McKesson Corporation (MCK) Up 5.9% — Time to Load Up?
McKesson Corporation (MCK) delivered one of the standout moves in the Health Care space this Thursday, climbing $50.63 to close at $904.44 on the NYSE. The rally puts the stock back within striking distance of its 52-week high of $999.00, set on March 3, 2026, and it now trades about 9.5% below that peak. It also sits roughly 25% above the bottom of its 52-week range of $723.68. A recovery of that size shows how firmly buyers have stepped back in after the stock pulled back from its spring highs.
Volume came in at 732,666 shares, below the 90-day average of roughly 1.04 million. The stock posted a near-6% gain on lighter-than-normal turnover, which suggests the advance met little resistance from sellers on the way up.
Why McKesson Corporation Price is Moving Higher
The driver was company-specific and clear. On October 1, McKesson announced an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health (CVS) through June 2032. The extension covers CVS mail-order, specialty and retail pharmacies as well as its distribution centers. That removes a major source of uncertainty around one of McKesson's longest-standing and most important customer relationships, and it gives investors a multi-year view of a large block of revenue. McKesson noted that the agreement in principle still needs to become a definitive contract. The market's response showed how much value investors place on keeping CVS in the fold.
The move clearly belonged to McKesson rather than the broader market. The S&P 500 slipped 0.25% and the Dow fell 0.86%, while the Nasdaq gained only 0.24%. Distribution peers shared in the good news. CVS also extended its agreement with Cardinal Health, Inc. (CAH), which rose 3.68%, and Cencora, Inc. (COR) gained 3.17%. McKesson's 5.93% advance was the strongest of the group, which points to its larger exposure to the CVS relationship. CVS Health Corporation itself slipped 0.57%.
Management also reaffirmed its fiscal 2027 adjusted EPS guidance of $44.20 to $45.00, along with its long-term target of 13% to 16% annual adjusted EPS growth. That outlook rests on a strong recent quarter. McKesson's August 5 report showed adjusted EPS of $9.93 against a $9.56 estimate, a 20% year-over-year increase. Revenue reached $105.38 billion versus the $103.88 billion consensus, up 8%. The company raised its full-year EPS range at that time, and Thursday's reaffirmation signals that the trajectory remains intact. Investors will get the next update when Q2 fiscal 2027 results are released after the market close on November 4, 2026.
What is the McKesson Corporation Rating - Should I Buy?
Weiss Ratings assigns MCK a B rating. The rating was upgraded on 9/4/2026. Current recommendation is Buy. The upgrade came a month after a quarter that beat on both the top and bottom lines and lifted full-year guidance. Thursday's CVS extension adds to that case by securing a key revenue source through mid-2032.
The fundamentals behind the rating are strong. McKesson is rated Excellent on the Growth Index, and the numbers support it. Revenue grew 7.72%, and quarterly sales rose from $96.30 billion in the March quarter to $105.38 billion in the June quarter, a 9.4% sequential increase. Few companies add nearly $9 billion in quarterly revenue from a base this large. The Excellent rating on the Efficiency Index matters even more given McKesson's 1.11% profit margin. Wholesale drug distribution is a volume business, and McKesson turns that thin spread into trailing EPS of $37.39 and 20% adjusted earnings growth. That reflects how well the company runs its pricing, logistics and cost structure at enormous scale. The Good rating on the Solvency Index indicates a balance sheet that can support continued investment in oncology and specialty platforms without strain.
Where the picture becomes more nuanced is in the market-based measures. The Total Return Index is rated Good. The stock has climbed roughly 25% off its 52-week low, which has rewarded holders, but it remains about 9.5% below its March high of $999.00. That gap is a key reason the rating is not higher. The Fair rating on the Volatility Index reflects the same pattern. Thursday's near-6% jump on a single customer announcement shows how sharply the stock can react to news about its largest relationships, in either direction. The stock trades at a forward P/E of 23.13, which keeps expectations elevated.
Within the Health Care sector, McKesson is on par with Cardinal Health, Inc. (CAH, B) and Labcorp Holdings Inc. (LH, B). It sits ahead of fellow distributor Cencora, Inc. (COR, B-) and its partner CVS Health Corporation (CVS, B-). Quest Diagnostics Incorporated (DGX, A-) carries a higher rating. Among the three major drug wholesalers, however, McKesson shares the top spot.
About McKesson Corporation
McKesson Corporation (MCK) is a Health Care company in the Health Care Equipment and Services industry. Founded in 1833 and headquartered in Irving, Texas, it is one of the largest pharmaceutical distributors in the world. The company operates through four segments. North American Pharmaceutical distributes branded, generic, specialty, biosimilar and over-the-counter drugs to retail pharmacies, hospitals, long-term care centers, clinics and institutions. It also provides logistics and distribution services for drug manufacturers. Oncology & Multispecialty serves the fast-growing cancer and specialty care markets with research, insights, technology and practice consulting services. That segment also handles gene therapy work through InspiroGene and vaccine distribution.
Prescription Technology Solutions addresses medication access, affordability and adherence. It connects patients, pharmacies, providers, pharmacy benefit managers, health plans and biopharma companies through services such as electronic prior authorization, prescription price transparency, benefit insight, dispensing support and patient enrollment. Medical-Surgical Solutions supplies medical-surgical products, laboratory equipment and pharmaceutical distribution to a wide range of providers. Its customers include physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health agencies, government facilities, and online marketplaces and retailers.
McKesson's competitive advantage comes from scale and integration. Its national distribution network, long-term contracts with major pharmacy chains, and position at the center of drug flows across the U.S. system create barriers that new entrants cannot easily overcome. Its growing presence in oncology and prescription technology adds higher-value services on top of the core distribution business. That mix gives McKesson deeper ties to manufacturers and providers and more ways to grow beyond pure drug volume.
Investor Outlook
McKesson Corporation (MCK) carries a Weiss Rating of B (Buy). The CVS extension, reaffirmed fiscal 2027 adjusted EPS guidance of $44.20 to $45.00, and strong recent results all support the bullish case. Investors should watch for the agreement in principle to become a definitive contract, and for the November 4 earnings release to confirm progress toward the 13% to 16% long-term EPS growth target as the stock works back toward its $999.00 high. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--